1998
The effect of lamotrigine on naloxone-precipitated opiate withdrawal
Rosen M, Pearsall H, Kosten T. The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug And Alcohol Dependence 1998, 52: 173-176. PMID: 9800147, DOI: 10.1016/s0376-8716(98)00057-x.Peer-Reviewed Original Research
1997
Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients
Rosen M, Pearsall H, Woods S, Kosten T. Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients. Journal Of Substance Use And Addiction Treatment 1997, 14: 149-154. PMID: 9258859, DOI: 10.1016/s0740-5472(96)00157-2.Peer-Reviewed Original ResearchDose Dependent Effects of Yohimbine on Methadone Maintained Patients
Hameedi F, Woods S, Rosen M, Pearsall H, Kosten T. Dose Dependent Effects of Yohimbine on Methadone Maintained Patients. The American Journal Of Drug And Alcohol Abuse 1997, 23: 327-333. PMID: 9143642, DOI: 10.3109/00952999709040950.Peer-Reviewed Original Research
1996
A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal
Rosen M, McMahon T, Woods S, Pearsall H, Kosten T. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. European Journal Of Pharmacology 1996, 307: 251-257. PMID: 8836612, DOI: 10.1016/0014-2999(96)00249-x.Peer-Reviewed Original ResearchConceptsNaloxone-precipitated opiate withdrawalOpiate withdrawalOpiate-dependent subjectsPre-clinical studiesConsiderable inter-individual variabilityPretreatment 1 hInter-individual variabilityIntramuscular naloxoneDextromethorphanPilot studyWithdrawal measuresPlaceboNaloxoneMethadoneWithdrawalSubjectsDifferent daysRandomized designEffect of clonidine pretreatment on naloxone-precipitated opiate withdrawal.
Rosen M, McMahon T, Hameedi F, Pearsall H, Woods S, Kreek M, Kosten T. Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. Journal Of Pharmacology And Experimental Therapeutics 1996, 276: 1128-35. PMID: 8786543.Peer-Reviewed Original ResearchConceptsClonidine pretreatmentOpiate withdrawalAdrenocorticotropic hormone (ACTH) responseDiastolic blood pressureNaloxone-precipitated opiate withdrawalNaloxone challenge testHeroin-dependent subjectsMeasures of withdrawalNasal congestionBlood pressureNew medicationsWithdrawal severityTesting medicationsChallenge testPlasma cortisolHormone responseConsecutive daysPilot studyClonidineMedicationsPositive controlWithdrawalBase linePretreatmentTwo-factor analysisThe Effect of Gamma-Hydroxybutyric Acid on Naloxone-Precipitated Opiate Withdrawal
Rosen M, Pearsall H, Woods S, Kosten T. The Effect of Gamma-Hydroxybutyric Acid on Naloxone-Precipitated Opiate Withdrawal. Neuropsychopharmacology 1996, 14: 187-193. PMID: 8866702, DOI: 10.1016/0893-133x(95)00087-t.Peer-Reviewed Original ResearchConceptsGamma-hydroxybutyric acidAnti-withdrawal effectSpontaneous opiate withdrawalOpiate withdrawalDouble-blind challengesNaloxone-precipitated opiate withdrawalGHB administrationGHB pretreatmentIntravenous naloxoneGHB effectsBalanced randomizationNaloxoneGABA metaboliteConsecutive daysWithdrawal measuresSignificant attenuationPrior studiesWithdrawalPretreatmentPlaceboMg/70InpatientsLevorphanolAdministration
1995
The Severity of Naloxone-Precipitated Opiate Withdrawal Is Attenuated by Felbamate, a Possible Glycine Antagonist
Kosten T, DeCaprio J, Rosen M. The Severity of Naloxone-Precipitated Opiate Withdrawal Is Attenuated by Felbamate, a Possible Glycine Antagonist. Neuropsychopharmacology 1995, 13: 323-333. PMID: 8747757, DOI: 10.1016/0893-133x(95)00065-l.Peer-Reviewed Original ResearchConceptsNaloxone-precipitated opiate withdrawalDose-related mannerOpiate withdrawalWithdrawal severityN-methyl-D-aspartate (NMDA) receptor systemPartial agonistOverall withdrawal severityGlycinergic agentsPenile groomingWithdrawal signsOpiate detoxificationHA-966NMDA antagonistsRostral medullaGlycine antagonistLow dosePotential treatmentPutative antagonistNMDA channelsClinical useReceptor systemAntagonistTeeth chatterD-cycloserineSeverityOpiate Dependence and Withdrawal: Preliminary Assessment Using Single Photon Emission Computerized Tomography (SPECT)
Krystal J, Woods S, Kosten T, Rosen M, Seibyl J, Van Dyck C, Price L, Zubal I, Hoffer P, Charney D. Opiate Dependence and Withdrawal: Preliminary Assessment Using Single Photon Emission Computerized Tomography (SPECT). The American Journal Of Drug And Alcohol Abuse 1995, 21: 47-63. PMID: 7762544, DOI: 10.3109/00952999509095229.Peer-Reviewed Original ResearchConceptsRegional brain functionOpiate withdrawal signsSingle Photon Emission Computerized TomographyHealthy subjectsNaloxone administrationOpiate withdrawalOpiate dependenceBrain functionParietal cortexHexamethylpropyleneamine oximeWithdrawal signsNaloxone effectChronic opiate dependencePlacebo-controlled studyRegional alterationsComparison of patientsMethadone-maintained patientsRegional cerebral perfusionPhoton Emission Computerized TomographyOpiate-dependent patientsRight temporal cortexRight parietal cortexFunctional brain imaging technologiesSingle photon emissionEmission computerized tomography
1994
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine
van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.Peer-Reviewed Original ResearchConceptsRegional cerebral blood flowRegional cerebral blood flow alterationsCerebral blood flow alterationsHexamethyl propylene amine oximeOpiate-induced analgesiaBlood flow alterationsSeverity of withdrawalCerebral blood flowOpiate-dependent patientsAnterior cingulate regionsAnterior cingulate cortexSingle photon emissionPlacebo administrationAmine oximeOpiate withdrawalRCBF ratiosWithdrawal severityBlood flowCingulate cortexCingulate regionsSignificant negative correlationBuprenorphineNaltrexonePlaceboPatients